Screener
aTyr Pharma ATYR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from aTyr Pharma’s reported figures.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
FAQ
- What is aTyr Pharma's EBITDA?
- aTyr Pharma (ATYR) reported EBITDA of -$10.71M in Q2 2026.
- How has aTyr Pharma's EBITDA changed year-over-year?
- aTyr Pharma's EBITDA increased by 46.8% year-over-year, from -$20.15M to -$10.71M.
- What is the long-term trend for aTyr Pharma's EBITDA?
- Over 4 years (2021 to 2025), aTyr Pharma's EBITDA has grown at a 23.1% compound annual growth rate (CAGR), from -$33.54M to -$76.96M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about aTyr Pharma's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude